CompletedPhase 2NCT00977665
Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)
Studying Multiple system atrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Principal Investigator
- Werner Poewe, ProfInnsbruck Medical University, Innsbruck, Austria
- Intervention
- rasagiline mesylate(drug)
- Enrollment
- 174 enrolled
- Eligibility
- 30 years · All sexes
- Timeline
- 2009 – 2011
Study locations (30)
- Teva Investigational Site 1004, Irvine, California, United States
- Teva Investigational Site 1014, La Jolla, California, United States
- Teva Investigational Site 1006, Sunnyvale, California, United States
- Teva Investigational Site 1010, Washington D.C., District of Columbia, United States
- Teva Investigational Site 1061, Boca Raton, Florida, United States
- Teva Investigational Site 1012, Tampa, Florida, United States
- Teva Investigational Site 1009, Worcester, Massachusetts, United States
- Teva Investigational Site 1003, Ann Arbor, Michigan, United States
- Teva Investigational Site 1007, Rochester, Minnesota, United States
- Teva Investigational Site 1011, St Louis, Missouri, United States
- Teva Investigational Site 1008, Rochester, New York, United States
- Teva Investigational Site 1001, Cleveland, Ohio, United States
- Teva Investigational Site 1002, Philadelphia, Pennsylvania, United States
- Teva Investigational Site 1013, Nashville, Tennessee, United States
- Teva Investigational Site 1005, Houston, Texas, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
H. Lundbeck A/S
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00977665 on ClinicalTrials.govOther trials for Multiple system atrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07446894MSA-01 in Multiple System AtrophyTokyo University
- RECRUITINGPHASE2NCT07197866An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System AtrophyTeva Branded Pharmaceutical Products R&D LLC
- ENROLLING BY INVITATIONNCT07081841AB-1005 Long-Term Follow-up StudyAskBio Inc
- RECRUITINGPHASE1, PHASE2NCT06831500Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease.Julien Bally
- RECRUITINGEARLY PHASE1NCT06765733The Study of Safety and Preliminary Efficacy of Aleeto in Patients With MultIple System AtrophyBeijing Tiantan Hospital
- RECRUITINGPHASE2NCT06868628A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)Tiziana Life Sciences LTD
- RECRUITINGNCT07353463Shanghai Clinical Cohort - Parkinson's Disease (Reserve)Ruijin Hospital
- RECRUITINGEARLY PHASE1NCT06891703[18F]ACI-15916 PET in α-synucleinopathiesAC Immune SA